Autoimmune Diseases
Dermpath Diagnosis
Recurrent Oral and Gluteal Cleft Erosions
A 71-year-old woman with no relevant medical history presented with recurrent painful erosions on the gingivae and gluteal cleft of 1 year’s...
Conference Coverage
Childhood lupus severity linked to social determinants of health
Social determinants of health were linked to lupus disease severity in children, but it will take more than awareness among doctors to address the...
Feature
New coalition aims to revolutionize stalled lupus research
Public-private consortium plans to develop new approaches to clinical studies.
Feature
Biosimilars and patients: Discussions should address safety, cost, and anxiety about change
Physicians can respond to pushback from patients on switching to a biosimilar by offering resources and discussing options for both biosimilar and...
Latest News
Anifrolumab shows promise in refractory discoid lupus erythematosus
Anifrolumab improved symptoms and activity of DLE within 2 months in a study of eight women.
From the Journals
CT results in myositis inform cancer screening strategies
Patients with the autoantibody anti–TIF1-gamma had the highest diagnostic yield, while patients under 40 years old had a high frequency of false...
Latest News
Novel therapy shows promise for treating skin-predominant dermatomyositis
The study drug “is a potent, selective humanized IgG1-neutralizing antibody directed at IFN-beta,” said Dr. Aaron Mangold, the principal...
Feature
Experts share real-world experience prescribing voclosporin, belimumab for lupus nephritis
While some rheumatologists expressed a treatment preference, patients with lupus nephritis tend to do well on both medications; however, cost and...
From the Journals
Autoantibodies signal reduced cancer risk in dermatomyositis
In patients with dermatomyositis positive for anti–TIF1-gamma autoantibodies, the presence of anti-CCAR1 autoantibodies indicate normal rather...
Latest News
New influx of Humira biosimilars may not drive immediate change
As many as 8-10 adalimumab biosimilars are anticipated to come on the market this year, giving mainstay drug Humira some vigorous competition.
Conference Coverage
New tool better estimates cardiovascular risk in people with lupus
A tool to estimate cardiovascular risk in systemic lupus erythematosus incorporates disease-specific variables.